2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Transcriptional Suppression of miR-7 by MTA2 Induces Sp1-Mediated KLK10 Expression and Metastasis of Cervical Cancer

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          MTA2 is involved in tumor proliferation and metastasis. However, the role of MTA2 in cervical cancer thus far has not been identified. In this study, we report that elevated expression of MTA2 negatively correlates with Kallikrein-10 (KLK10) expression and poor prognosis of cervical cancer patients. Knockdown of MTA2 substantially inhibited tumor cell migration and invasion, and it enhanced KLK10 expression of the cervical cancer cells in vitro and in vivo. Functionally, shMTA2-mediated suppression of cell mobility was significantly restored by knockdown of KLK10. We also found that Sp1 (transcription factor specificity protein 1) is critical for shMTA2-induced transcriptional upregulation of KLK10 and subsequent biological functions. Furthermore, we found that the expression of miR-7 is elevated by MTA2 silencing and then by direct inhibition of Sp1 expression. Knockdown of Sp1 additively enhanced KLK10 expression in MTA2-knocked down cervical cancer cells, suggesting that the miR-7/Sp1 axis acts as an effector of MTA2 to impact KLK10 levels and mobility of cervical cancer cells. Taken together, our findings provide new insights into the physiological relationship between MTA2 and KLK10 via regulating the miR-7/Sp1 axis, and they provide a potential therapeutic target in cervical cancer.

          Graphical Abstract

          Abstract

          In vitro and in vivo studies revealed that knockdown of MTA2 inhibits metastasis of cervical cancer through induction of miR-7 targeting Sp1/KLK10 expression. These finding provide novel molecular mechanistic insight on the MTA2/miR-7/Sp1/KLK10 axis and its potential therapeutic target in cervical cancer.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: found
          • Article: not found

          SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities.

          SET8 is implicated in transcriptional regulation, heterochromatin formation, genomic stability, cell-cycle progression, and development. As such, it is predicted that SET8 might be involved in the development and progression of tumour. However, whether and how SET8 might be implicated in tumourigenesis is currently unknown. Here, we report that SET8 is physically associated with TWIST, a master regulator of epithelial-mesenchymal transition (EMT). We demonstrated that SET8 and TWIST are functionally interdependent in promoting EMT and enhancing the invasive potential of breast cancer cells in vitro and in vivo. We showed that SET8 acts as a dual epigenetic modifier on the promoters of the TWIST target genes E-cadherin and N-cadherin via its H4K20 monomethylation activity. Significantly, in breast carcinoma samples, SET8 expression is positively correlated with metastasis and the expression of TWIST and N-cadherin and negatively correlated with E-cadherin. Together, our experiments revealed a novel role for SET8 in tumour invasion and metastasis and provide a molecular mechanism underlying TWIST-promoted EMT, suggesting SET8 as a potential target for intervention of the metastasis of breast cancer.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Systemic therapy in cervical cancer: 30 years in review

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Metastasis-associated protein 1/nucleosome remodeling and histone deacetylase complex in cancer.

              Cancer cells frequently exhibit deregulation of coregulatory molecules to drive the process of growth and metastasis. One such group of ubiquitously expressed coregulators is the metastasis-associated protein (MTA) family, a critical component of the nucleosome remodeling and histone deacetylase (NuRD) complex. MTA1 occupies a special place in cancer biology because of its dual corepressor or coactivator nature and widespread overexpression in human cancers. Here, we highlight recent advances in our understanding of the vital roles of MTA1 on transformation, epithelial-mesenchymal transition, and the functions of key cancer-relevant molecules such as a nexus of multiple oncogenes and tumor suppressors. In addition to its paramount role in oncogenesis, we reveal several new physiologic functions of MTA1 related to DNA damage, inflammatory responses, and infection, in which MTA1 functions as a permissive "gate keeper" for cancer-causing parasites. Further, these discoveries unraveled the versatile multidimensional modes of action of MTA1, which are independent of the NuRD complex and/or transcription. Given the emerging roles of MTA1 in DNA repair, inflammation, and parasitism, we discuss the possibility of MTA1-targeted therapy for use not only in combating cancer but also in other inflammation and pathogen-driven pathologic conditions.
                Bookmark

                Author and article information

                Contributors
                Journal
                Mol Ther Nucleic Acids
                Mol Ther Nucleic Acids
                Molecular Therapy. Nucleic Acids
                American Society of Gene & Cell Therapy
                2162-2531
                28 April 2020
                05 June 2020
                28 April 2020
                : 20
                : 699-710
                Affiliations
                [1 ]Institute of Biochemistry, Microbiology, and Immunology, Chung Shan Medical University, Taichung, Taiwan
                [2 ]Department of Surgery, MacKay Memorial Hospital and Mackay Medical College, New Taipei City, Taiwan
                [3 ]Department of Obstetrics and Gynecology, Chung Shan Medical University Hospital, Taichung, Taiwan
                [4 ]Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan
                [5 ]Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan
                [6 ]Department of Medicine, Mackay Medical College, New Taipei City, Taiwan
                [7 ]Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan
                [8 ]Graduate Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan
                [9 ]Department of Pharmacology, Taipei Medical University, Taipei, Taiwan
                [10 ]Department of Biochemistry, School of Medicine, Chung Shan Medical University, Taichung, Taiwan
                [11 ]Clinical Laboratory, Chung Shan Medical University Hospital, Taichung, Taiwan
                Author notes
                []Corresponding author: Jie-Jen Lee, Department of Surgery, MacKay Memorial Hospital and Mackay Medical College, No. 46, Section 3, Zhongzheng Road, Sanzhi District, New Taipei City, Taiwan. jjlee918@ 123456mmc.edu.tw
                [∗∗ ]Corresponding author: Yi-Hsien Hsieh, Department of Biochemistry, School of Medicine, Chung Shan Medical University, No. 110, Section 1, Jianguo North Road, Taichung City, Taiwan. hyhsien@ 123456csmu.edu.tw
                Article
                S2162-2531(20)30117-7
                10.1016/j.omtn.2020.04.009
                7218230
                32402941
                ceb3e510-fb04-4a7b-bbae-2e8f6de6d375
                © 2020 The Author(s)

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 1 March 2020
                : 22 April 2020
                Categories
                Article

                Molecular medicine
                mta2,klk10,sp1,mirna-7,cervical cancer
                Molecular medicine
                mta2, klk10, sp1, mirna-7, cervical cancer

                Comments

                Comment on this article